Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
Abstract
Importance
To date, the benefit of genome-driven cancer therapy has not been quantified.Objective
We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven therapy from 2006 to 2018.Design, Setting, and Participants
Retrospective cross-sectional study using...Paper Details
Title
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
Published Date
Aug 1, 2018
Journal
Volume
4
Issue
8
Pages
1093 - 1093
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History